Relationship between metabolic syndrome and follicle-stimulating hormone in postmenopausal women

• Published in: Medicine (Baltimore) 2022-05, Vol.101 (18), p.e29216-e29216
• Main Authors: Lee, Suk Woo, Hwang, In Sun, Jung, Gyul, Kang, Hee Jin, Chung, Yoo Hyun
• Format: Article
• Language: English
• Subjects: Adiponectin; Estradiol; Female; Follicle Stimulating Hormone; Humans; Insulin Resistance - physiology; Metabolic Syndrome - epidemiology; Observational Study; Postmenopause
• ISSN: 0025-7974; 1536-5964
• DOI: 10.1097/MD.0000000000029216

Depletion of ovarian reserve during menopausal transition raises follicle-stimulating hormone (FSH) markedly and menopause is related to an increased risk for metabolic syndrome (MetS). This study examined the relationship between FSH and MetS in postmenopausal women.We evaluated the anthropometric values, lipid profiles, high-sensitivity C-reactive protein (hs-CRP) level, Homeostasis model assessment for insulin resistance (HOMA-IR), and serum adipokines levels in 219 postmenopausal women. Serum FSH and estradiol levels were significantly lower in the MetS group than in the non-MetS group. An inverse correlation was observed between FSH with body fat mass (BFM), and HOMA-IR, and a positive correlation was found between FSH and adiponectin level after adjustment for age, years since menopause, BMI, and serum estradiol.The odds ratio for MetS was higher significantly in the lowest quartile of FSH level than the highest quartile of FSH level (odd ratio = 1.32, 95% CI = 1.09-1.75). Our study showed an increased FSH level favored insulin sensitivity with a higher adiponectin and lower HOMA-IR as well as a lower incidence of MetS in postmenopausal women.These findings suggest a new approach to the role of FSH for regulating energy metabolism and for use as a biomarker of MetS risk in postmenopausal women.This systematic review is based on published researches, so there is no ethical approval required.